MX369217B - Compuesto de triazina y su uso para propositos medicos. - Google Patents

Compuesto de triazina y su uso para propositos medicos.

Info

Publication number
MX369217B
MX369217B MX2016010875A MX2016010875A MX369217B MX 369217 B MX369217 B MX 369217B MX 2016010875 A MX2016010875 A MX 2016010875A MX 2016010875 A MX2016010875 A MX 2016010875A MX 369217 B MX369217 B MX 369217B
Authority
MX
Mexico
Prior art keywords
triazine compound
medical purposes
compound
mpges
rheumatism
Prior art date
Application number
MX2016010875A
Other languages
English (en)
Other versions
MX2016010875A (es
Inventor
Yuichi Nakagawa
Masaki Yamashita
Ikuo Mitani
Takahiro Hotta
Hironobu Nagamori
Ueda Masatoshi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2016010875A publication Critical patent/MX2016010875A/es
Publication of MX369217B publication Critical patent/MX369217B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporciona un compuesto que tiene una actividad inhibidora de mPGES-1 y que es de utilidad para la prevención o el tratamiento de dolor, reumatismo, osteoartritis, fiebre, enfermedad de Alzheimer, esclerosis múltiple, arteriosclerosis, glaucoma, hipertensión ocular, enfermedad retinal isquémica, esclerodermia sistémica y cáncer, incluyendo cáncer colorrectal; un compuesto representado por la fórmula [I] o una de sus sales farmacéuticamente aceptables: (ver Fórmula) en donde cada símbolo es como se define en la memoria descriptiva.
MX2016010875A 2014-02-20 2015-02-19 Compuesto de triazina y su uso para propositos medicos. MX369217B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014031035 2014-02-20
PCT/JP2015/054519 WO2015125842A1 (ja) 2014-02-20 2015-02-19 トリアジン化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
MX2016010875A MX2016010875A (es) 2016-10-26
MX369217B true MX369217B (es) 2019-10-31

Family

ID=53878341

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010875A MX369217B (es) 2014-02-20 2015-02-19 Compuesto de triazina y su uso para propositos medicos.

Country Status (31)

Country Link
US (3) US20150266834A1 (es)
EP (2) EP3109240B1 (es)
JP (4) JP6461637B2 (es)
KR (1) KR102360699B1 (es)
CN (1) CN106232585B (es)
AR (1) AR099498A1 (es)
AU (1) AU2015219920B2 (es)
BR (1) BR112016018341B1 (es)
CA (1) CA2936408C (es)
CL (1) CL2016002091A1 (es)
CY (1) CY1121261T1 (es)
DK (1) DK3109240T3 (es)
ES (1) ES2704922T3 (es)
HR (1) HRP20182134T1 (es)
IL (1) IL247319B (es)
LT (1) LT3109240T (es)
MX (1) MX369217B (es)
MY (1) MY183605A (es)
PE (2) PE20161236A1 (es)
PH (1) PH12016501651A1 (es)
PL (1) PL3109240T3 (es)
PT (1) PT3109240T (es)
RS (1) RS58235B1 (es)
RU (1) RU2692789C2 (es)
SA (1) SA516371701B1 (es)
SG (1) SG11201606902QA (es)
SI (1) SI3109240T1 (es)
TR (1) TR201821158T4 (es)
TW (1) TWI651310B (es)
WO (1) WO2015125842A1 (es)
ZA (1) ZA201606449B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
EP3224237A4 (en) * 2014-12-24 2018-02-07 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
JP6478255B2 (ja) * 2015-03-04 2019-03-06 株式会社島津製作所 蛍光誘導体化試薬及びアミン分析方法
BR112018001809A2 (pt) * 2015-08-17 2018-09-18 Japan Tobacco, Inc. composto de hidroxitriazina e uso médico do mesmo
CA3002632C (en) 2015-10-29 2023-08-29 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
GB201603311D0 (en) * 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
WO2018026763A1 (en) * 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3645527A1 (de) * 2017-06-26 2020-05-06 Merck Patent GmbH Verfahren zur herstellung substituierter stickstoffhaltiger heterocyclen
AU2020316364A1 (en) * 2019-07-22 2022-02-24 Angion Biomedica Corp. Ethynylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
US11786538B2 (en) * 2019-12-11 2023-10-17 Somerset Therapeutics, Llc Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties
KR102157466B1 (ko) * 2020-05-19 2020-09-17 동아대학교 산학협력단 헥사하이드로트리아진 유도체를 포함하는 방광암의 예방, 개선 또는 치료용 조성물
JP7277676B2 (ja) 2021-02-02 2023-05-19 あすか製薬株式会社 ピリミジン誘導体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981003020A1 (en) * 1980-04-22 1981-10-29 Commw Scient Ind Res Org Triazine synthesis
DE19543730A1 (de) * 1995-11-23 1997-05-28 Ciba Geigy Ag Bis-Resorcinyl-Triazine
CN1246858A (zh) * 1996-12-05 2000-03-08 安姆根有限公司 取代的嘧啶化合物和它们的应用
TW520362B (en) * 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
US20040082627A1 (en) * 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
EP2138488A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
CN101747282A (zh) * 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
US8952150B2 (en) * 2009-09-23 2015-02-10 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors and uses thereof
AR086254A1 (es) 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
FR2983859B1 (fr) * 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
CN115536635A (zh) * 2012-01-06 2022-12-30 法国施维雅药厂 治疗活性化合物及其使用方法
TWI568722B (zh) * 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
JP2014031035A (ja) 2012-08-01 2014-02-20 Yamaha Motor Co Ltd 原動機付き鞍乗型車両
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
CN105586773A (zh) * 2014-11-13 2016-05-18 东丽纤维研究所（中国）有限公司 一种拒水抗紫外纺织品及其生产方法和用途

Also Published As

Publication number Publication date
KR102360699B1 (ko) 2022-02-10
TR201821158T4 (tr) 2019-01-21
SG11201606902QA (en) 2016-09-29
EP3109240A4 (en) 2017-07-26
AU2015219920B2 (en) 2018-12-20
MX2016010875A (es) 2016-10-26
NZ721718A (en) 2021-08-27
JP2019065036A (ja) 2019-04-25
CL2016002091A1 (es) 2017-01-20
CN106232585B (zh) 2019-04-02
RU2016137263A3 (es) 2018-10-04
WO2015125842A1 (ja) 2015-08-27
AU2015219920A1 (en) 2016-07-14
RU2016137263A (ru) 2018-03-23
LT3109240T (lt) 2019-01-10
JP6461637B2 (ja) 2019-01-30
US20200087266A1 (en) 2020-03-19
US20230011968A1 (en) 2023-01-12
RS58235B1 (sr) 2019-03-29
JP2021054856A (ja) 2021-04-08
CA2936408C (en) 2022-09-13
PH12016501651B1 (en) 2017-02-06
CY1121261T1 (el) 2020-05-29
TWI651310B (zh) 2019-02-21
RU2692789C2 (ru) 2019-06-27
ES2704922T3 (es) 2019-03-20
ZA201606449B (en) 2017-11-29
EP3109240B1 (en) 2018-10-24
CN106232585A (zh) 2016-12-14
DK3109240T3 (en) 2018-12-17
MY183605A (en) 2021-03-02
PT3109240T (pt) 2019-01-21
BR112016018341A2 (es) 2017-08-08
KR20160113727A (ko) 2016-09-30
EP3109240A1 (en) 2016-12-28
AR099498A1 (es) 2016-07-27
SA516371701B1 (ar) 2019-01-21
PE20161236A1 (es) 2016-11-23
HRP20182134T1 (hr) 2019-02-08
IL247319A0 (en) 2016-09-29
BR112016018341B1 (pt) 2023-02-07
SI3109240T1 (sl) 2019-02-28
PL3109240T3 (pl) 2019-03-29
TW201620881A (zh) 2016-06-16
PE20211548A1 (es) 2021-08-16
EP3456713A1 (en) 2019-03-20
JP2015172039A (ja) 2015-10-01
PH12016501651A1 (en) 2017-02-06
IL247319B (en) 2019-11-28
JP2022120173A (ja) 2022-08-17
US20150266834A1 (en) 2015-09-24
CA2936408A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
PH12016501651A1 (en) Triazine compound and use thereof for medical purposes
PH12020551305A1 (en) Pharmaceutical Compounds
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
TN2018000218A1 (en) Indole carboxamides compounds useful as kinase inhibitors.
WO2016198531A3 (en) Hpv vaccines
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
EA201990833A1 (ru) Соединение пиридина
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
PH12017500095A1 (en) Imidazopyridazine compounds
WO2016004404A3 (en) Gls1 inhibitors for treating disease
JO3789B1 (ar) التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
WO2016004413A3 (en) Gls1 inhibitors for treating disease
PH12018500181A1 (en) Hydroxytriazine compound and medical use thereof
PH12015502744A1 (en) Bicyclic nitrogen-containing aromatic heterocyclic amide compound
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
WO2015155680A3 (en) Pyrazole derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors
PH12016502432A1 (en) 1h-1,8-naphthyridin-2-ones as anti proliferative compounds
TN2017000448A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
PH12019502792A1 (en) Tetrahydropyridopyrazine modulators of gpr6
EA037533B9 (ru) 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
UA123899U (uk) Застосування солей тіазолію як агентів, що інгібують активність ацетилхолінестерази і бутирилхолінестерази
WO2008084081A3 (en) 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders

Legal Events

Date Code Title Description
FG Grant or registration